TrialAnnals of hematology2023

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.

Ulrich Germing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.